These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28301428)

  • 1. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.
    Walters TD; Faubion WA; Griffiths AM; Baldassano RN; Escher J; Ruemmele FM; Hyams JS; Lazar A; Eichner S; Huang B; Li Y; Thakkar RB
    Inflamm Bowel Dis; 2017 Jun; 23(6):967-975. PubMed ID: 28301428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.
    Pichler J; Huber WD; Aufricht C; Bidmon-Fliegenschnee B
    World J Gastroenterol; 2015 Jun; 21(21):6613-20. PubMed ID: 26074699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA; Dubinsky M; Ruemmele FM; Escher J; Rosh J; Hyams JS; Eichner S; Li Y; Reilly N; Thakkar RB; Robinson AM; Lazar A
    Inflamm Bowel Dis; 2017 Mar; 23(3):453-460. PubMed ID: 28129288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.
    Ruemmele FM; Rosh J; Faubion WA; Dubinsky MC; Turner D; Lazar A; Eichner S; Maa JF; Alperovich G; Robinson AM; Hyams JS
    J Crohns Colitis; 2018 Nov; 12(10):1249-1254. PubMed ID: 29939254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial.
    Matar M; Shamir R; Lev-Zion R; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Assa A
    J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):237-242. PubMed ID: 32324651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease].
    Navas-López VM; Pujol Muncunill G; Llerena E; Navalón Rubio M; Gil-Ortega D; Varea-Calderón V; Sierra Salinas C; Martin-de-Carpi J
    An Pediatr (Engl Ed); 2018 Feb; 88(2):89-99. PubMed ID: 28434894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adalimumab as induction therapy for Crohn's disease - one center study].
    Gonciarz M; Mularczyk A; Szkudłapski D; Piątek I; Kopała M
    Pol Merkur Lekarski; 2016 Nov; 41(245):216-220. PubMed ID: 27883347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
    Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
    Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
    J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
    Sandborn WJ; Colombel JF; Schreiber S; Plevy SE; Pollack PF; Robinson AM; Chao J; Mulani P
    Inflamm Bowel Dis; 2011 Jan; 17(1):141-51. PubMed ID: 20848500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.